Journal of Cancer Policy最新文献

{"title":"Integrating cancer education into Tunisian school curricula: A public health necessity","authors":"Foued Maaoui , Imen Moumni, Ines Safra, Samia Menif","doi":"10.1016/j.jcpo.2025.100606","DOIUrl":"10.1016/j.jcpo.2025.100606","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100606"},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer treatment amid armed conflict: Challenges and urgent needs in Sudan","authors":"Moawia Mohammed Ali Elhassan ,&nbsp;Amal Abdulbagi Abdulfatah Mohammed ,&nbsp;Fatima kamaleldeen Osman Muhyeldeen ,&nbsp;Esra Noah Sulieman Algadam ,&nbsp;Alkhansaà Hider Mouhamed Bakheet Mouhamed ,&nbsp;Manal Elzubair Elmahdi Ibrahim ,&nbsp;Sahar Mohammed Idris Sayed","doi":"10.1016/j.jcpo.2025.100604","DOIUrl":"10.1016/j.jcpo.2025.100604","url":null,"abstract":"<div><h3>Background</h3><div>The ongoing armed conflict in Sudan has severely disrupted healthcare, particularly cancer care, where continuous treatment is vital. Cancer patients face significant challenges, including treatment delays, shortages of essential drugs, and limited access to healthcare professionals. Despite growing research on cancer care in conflict settings, data specific to Sudan remains scarce.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted between September and November 2024 at Dr. Tiraky Oncology Center in Kassala State, Sudan. Data were collected using a structured questionnaire, covering demographic characteristics, treatment disruptions, drug availability, and financial burden. Descriptive statistics were used for data analysis.</div></div><div><h3>Results</h3><div>Of 100 patients, chemotherapy interruptions affected 89 %, mainly due to displacement (52 %) and transportation barriers (29 %). Essential cancer medicines were frequently unavailable, significantly disrupting treatment continuity. International donations have provided some relief, though no strategy has completely resolved the issue. While the government covers the cost of essential cancer medicines, patients and their families must bear additional expenses, particularly for out-of-stock chemotherapy drugs, transportation and accommodation. Additional challenges included, staff shortages, limited chemotherapy chairs (n = 12) and increased workload. Financial burdens were significant, with the average cost of a single chemotherapy cycle per patient estimated at $900.</div></div><div><h3>Conclusions</h3><div>The findings highlight the severe impact of ongoing conflict on cancer care in Sudan, emphasizing the need for urgent interventions. Strengthening supply chains, expanding treatment capacity, and providing financial and logistical support are critical to mitigating the conflict’s effects on patients from conflict-affected regions.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100604"},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and Solutions of Cancer Registries: A Scoping Review.","authors":"Raziehsadat Mousavi, Naser Derakhshani, Abbas Sheikhtaheri, Gholamreza Roshandel, Asgar Aghaei Hashjin","doi":"10.1016/j.jcpo.2025.100607","DOIUrl":"https://doi.org/10.1016/j.jcpo.2025.100607","url":null,"abstract":"<p><strong>Background: </strong>Globally, cancer will develop in one of every five people during their lifetime, impacting families in multiple ways. Despite the long history of cancer registries, dating back to the early 20th century, they face persistent challenges, such as limited resources, insufficient data, governance failure, and operational inefficiency. These challenges hinder effective cancer control and public health planning. Overcoming them is crucial for improving management, enhancing policymaking, and providing more accurate statistics, thus enabling a clearer assessment of the cancer burden. This study aimed to investigate the challenges faced by cancer registry programs and propose effective solutions to enhance their performance and accuracy.</p><p><strong>Methods: </strong>This scoping review was conducted across PubMed, Scopus, Web of Knowledge, Embase, ProQuest, SID, MagIran, and Google Scholar. We searched for articles published between January 2000 and December 2024. The review process was conducted between July 1 and December 25, 2024. EndNote (version 21) was used for reference management and data organization. The methodology involved reference list reviewing, grey literature searching, and hand-searching, complemented by content analysis. Predefined eligibility criteria guided the screening process, where only full-text articles published no later than 2024 and written in English or Persian were included.</p><p><strong>Results: </strong>Cancer registry programs were found to face multiple challenges in four key areas: resources (human and financial), data (collection, analysis, and reporting), governance (population coverage and infrastructure), and procedures (communication and standardization). The proposed solutions included hiring full-time staff, allocating direct funding, implementing effective data management systems, ensuring comprehensive population coverage, building a robust program infrastructure, raising awareness among policymakers, and standardizing forms and procedures.</p><p><strong>Conclusion: </strong>This study identified key challenges in cancer registry programs, underscoring the need for effective management and improved infrastructure. Addressing issues such as resource shortages and data inefficiencies can significantly enhance program performance. Strengthening communication and standardizing processes will directly contribute to better health policy and cancer control efforts.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100607"},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First tobacco-free generation in Europe – A lost cause? Latest Global Youth Tobacco Survey data from Poland and the CEE region","authors":"Irmina Maria Michalek ,&nbsp;Joanna Didkowska ,&nbsp;Paweł Koczkodaj","doi":"10.1016/j.jcpo.2025.100601","DOIUrl":"10.1016/j.jcpo.2025.100601","url":null,"abstract":"<div><h3>Background</h3><div>Tobacco use remains a significant public health issue among adolescents worldwide, now exacerbated by the rise of alternative nicotine products like electronic cigarettes and heated tobacco. Monitoring these trends is essential for effective public health response. This study presents the latest data on tobacco and electronic cigarette use, as well as secondhand smoke exposure, among Polish adolescents aged 13–15.</div></div><div><h3>Methods</h3><div>In 2022 we conducted a cross-sectional study within the framework of the Global Youth Tobacco Survey (GYTS), which uses a standardized two-stage sampling methodology. Data were collected from a nationally representative sample of 3573 students aged 13–15 in Poland. The survey assessed current and ever-use of conventional and alternative tobacco products, secondhand smoke exposure, and attitudes toward tobacco. Weighted estimates were used to ensure national representativeness.</div></div><div><h3>Results</h3><div>Among Polish adolescents, 17.1 % reported current use of any tobacco product, with a similar prevalence among boys (17.3 %) and girls (16.9 %). Current electronic cigarette use was notably high at 22.3 %, with higher usage among girls (23.4 %) than boys (21.2 %). Secondhand smoke exposure at home affected 28.8 % of students. Comparison with previous GYTS data indicates declining traditional tobacco use but a rise in alternative product use.</div></div><div><h3>Conclusions</h3><div>Our findings highlight the need for updated tobacco control policies in Poland that address both traditional and alternative nicotine products. The high prevalence of electronic cigarette use among adolescents is particularly concerning and calls for targeted interventions and public health education aimed at reducing youth access and appeal of these products.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100601"},"PeriodicalIF":2.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden of skin cancer in Southern Iran: A cost-of-illness study","authors":"Faride Sadat Jalali ,&nbsp;Khosro Keshavarz ,&nbsp;Mozhgan Seif ,&nbsp;Abdosaleh Jafari ,&nbsp;Ramin Ravangard","doi":"10.1016/j.jcpo.2025.100602","DOIUrl":"10.1016/j.jcpo.2025.100602","url":null,"abstract":"<div><h3>Background</h3><div>Skin cancer is one of the most common cancers around the world, which imposes a great economic burden on patients and societies. The present study aimed at determining the economic burden of skin cancer in patients referred to diagnostic and treatment centers in southern Iran in 2021.</div></div><div><h3>Methods</h3><div>This was a partial economic evaluation of the cost-of-illness type conducted from the societal perspective with the bottom-up and prevalence-based approaches. A total of 108 patients were included through the simple random sampling method, and a researcher-made data collection form was used to collect the required data. The data on direct medical costs were obtained by using the patient’s medical and financial records, as well as the data on direct medical and indirect costs were collected by asking the patients or their companions on the phone.</div></div><div><h3>Results</h3><div>The results showed that the annual cost of each skin cancer patient in the studied sample was 7699.76 USD in 2021. The indirect costs accounted for the largest share of costs (72.85 %), of which the costs of premature death were the highest. The costs of direct medical and direct non-medical costs were 19.77 % and 7.38 %, respectively, and the economic burden of the disease in the country was estimated at 569,550,508 USD in that year.</div></div><div><h3>Conclusions</h3><div>The economic burden of skin cancer in Iran is very high. Some suggestions to reduce its costs and economic burden include providing specialized services in high-incidence cities, virtual follow-ups, screening services, and sun safety interventions.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100602"},"PeriodicalIF":2.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144170285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in Morocco: State of art and challenges for implementation","authors":"Meriem Khyatti ,&nbsp;Fouzia Radouani ,&nbsp;Ichrak Benamri ,&nbsp;Amina Gihbid ,&nbsp;Hicham Charoute ,&nbsp;Adil El Hamouchi ,&nbsp;Imane Chaoui ,&nbsp;Abdellatif Benider ,&nbsp;Nadia Benchakroun ,&nbsp;Hicham El Attar ,&nbsp;Khaoula Errafii ,&nbsp;Tariq Daouda ,&nbsp;Mohammed El Mzibri ,&nbsp;Abdelhamid Barakat ,&nbsp;Moroccan PerMediNA Consortium","doi":"10.1016/j.jcpo.2025.100598","DOIUrl":"10.1016/j.jcpo.2025.100598","url":null,"abstract":"<div><div>Precision Medicine (PM) is an innovative approach that takes into account individuals' genetic differences, environments, and lifestyles to provide personalised patient care. Policy development for PM implementation requires assessing a wide range of issues extending from knowledge and skills in terms of OMICs, specimen collection and management, as well as data analyses and sharing to whether and how to utilise advanced technologies for diagnosis, clinical practice and diverse public health initiatives. For this purpose, within the “Personalized Medicine in North Africa” (PerMediNA) project, we conducted a survey among Moroccan scientists, physicians, and stakeholders with an interest in genomics and PM. The survey aimed to evaluate their knowledge and understanding of the field, the institutional environment and infrastructure availability, the state and awareness of the field in their contexts, information dissemination to potential users, training programs, and capacity building for specialised personnel, as well as engaging political stakeholders and policymakers. As a summary, based on various stakeholders’ feedback, in addition to our effort in exploring the challenges faced when putting in place genomic medicine programs, we were enabled to formulate feasible recommendations that may be applicable to start the process of implementing and strengthening PM in the Moroccan context.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100598"},"PeriodicalIF":2.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations of perioperative systemic therapies considering age or comorbidities in the National Comprehensive Cancer Network (NCCN) guidelines and quality of cited evidence.","authors":"Sruthi Ranganathan, Myung Sun Kim, Timothee Olivier, Alyson Haslam, Vinay Prasad","doi":"10.1016/j.jcpo.2025.100600","DOIUrl":"https://doi.org/10.1016/j.jcpo.2025.100600","url":null,"abstract":"<p><strong>Importance: </strong>Perioperative therapy for cancer is offered to reduce the recurrence and improve overall long-term outcomes. Age and comorbidities of patients can influence the effectiveness and/or safety of perioperative therapy. It is important that key national guidelines, such as the National Comprehensive Cancer Network (NCCN) guidelines, reflect the benefit of perioperative therapy for key subpopulations of patients. However, this has not been evaluated.</p><p><strong>Objective: </strong>To evaluate the perioperative treatment guidance, with regards to age and comorbidities, reported in the NCCN guidelines DESIGN SETTING, AND PARTICIPANTS: NCCN age and comorbidity in perioperative treatment guidelines.</p><p><strong>Intervention: </strong>Age and Comorbidities MAIN OUTCOME AND MEASURE: The existence of age or comorbidity-specific guidelines for perioperative therapy, the presence of literature support for these specific guidelines, and where they exist.</p><p><strong>Results: </strong>Only 2 of the 10 cancer types studied had specific guidelines on perioperative therapy based on age, and 4/10 had guidelines on perioperative therapy considering patients' comorbidities. 5 of the 10 cancer guidelines and 4/10 had vague advice on consideration of age and comorbidities respectively. A total of 30 recommendations made across the guidelines studied. Studies that are cited to support these recommendations were often pooled analyses of RCTs or subgroup analysis of randomized controlled trials (RCTs) (33%).</p><p><strong>Conclusion and relevance: </strong>This study shows the lack of age and comorbidity-specific guidelines for many cancer types in the NCCN guidelines. In addition, several of these recommendations, where they exist, are also not supported by strong evidence such as RCTs. There is a need for more comprehensive guidelines that make recommendations accounting for patient-intrinsic factors.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100600"},"PeriodicalIF":2.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bhutan achieves the 90-70-90 targets on the path to elimination of cervical cancer: Experience, challenges and way forward","authors":"Namkha Dorji ,&nbsp;Thinley Dorji ,&nbsp;Yeshey Dorjey ,&nbsp;Sangay Tshering ,&nbsp;Yangdon Yangdon ,&nbsp;Cheten Zangmo","doi":"10.1016/j.jcpo.2025.100596","DOIUrl":"10.1016/j.jcpo.2025.100596","url":null,"abstract":"<div><div>Cervical cancer is the most common form of cancers among females in Bhutan. The Royal Government of Bhutan has achieved the 90–70–90 global milestones towards elimination of cervical cancer. However, challenges remain in improving the quality of services, and addressing sustainability issues. With continued political commitment, dedicated efforts of health professionals and public support, Bhutan is committed in our efforts towards elimination of invasive cervical cancer by 2030, in alignment with the World Health Organization’s global target. This review article presents the efforts, challenges and way forward towards elimination of cervical cancer in Bhutan.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100596"},"PeriodicalIF":2.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Characteristics of Immunoncology Drugs Appraised by NICE and SMC: A Retrospective Analysis 2012-2023.","authors":"Giannis Agorastos, Elpida Pavi, Athanassios Vozikis, Kostas Athanasakis","doi":"10.1016/j.jcpo.2025.100599","DOIUrl":"https://doi.org/10.1016/j.jcpo.2025.100599","url":null,"abstract":"<p><strong>Introduction: </strong>Immunoncology has revolutionized cancer treatment by offering improved survival and quality of life. This study aimed to explore the characteristics of NICE and SMC's decisions for the reimbursement of immunoncology drugs, within the healthcare systems of the UK & Wales and Scotland respectively.</p><p><strong>Methods: </strong>The classification of the Cancer Research Institute was used, to identify immunoncology drugs. A systematic search of publicly available HTA decisions on immunoncology drugs was performed, taking into account technology appraisals conducted from 2012 to 2023. Data on drug-indication pairs, recommendation status and ICER for both NICE and SMC appraisals, were extracted in standardized tables. A retrospective analysis of the reviewed decisions was conducted.</p><p><strong>Results: </strong>A total of 58 NICE and 57 SMC appraisals were analyzed, revealing that most decisions were positive or optimised/restricted (91.4% and 87.7%, respectively). Lung cancer and melanoma were the most frequently appraised indications. More than half of the appraisals (53.4% for NICE and 61.4% for SMC) reported ICERs above £30,000 per QALY. Patient group submissions were included in 89.7% of NICE and all SMC decisions, reflecting the agencies' commitment to incorporating patient perspectives. Policy summary: The number of immunoncology drugs assessed by NICE and SMC has increased significantly in the latest years, reflecting their expanding use across a broad range of cancer indications. This study highlights the high acceptance rates of immunoncology therapies appraised by both agencies, as well as the link between high ESMO-MCBS score (for both curative and non-curative and non-curative settings) and positive or optimised/restricted coverage recommendations. By exploring the characteristics of immunoncology drugs appraisals, the analysis provides insights into the evolving landscape of this therapeutic area.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100599"},"PeriodicalIF":2.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to rethink cancer care and research in Africa with new tactics","authors":"Khalid El Bairi,&nbsp;Abigiya Wondimagegnehu,&nbsp;Omar Abdihamid","doi":"10.1016/j.jcpo.2025.100595","DOIUrl":"10.1016/j.jcpo.2025.100595","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100595"},"PeriodicalIF":2.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}